Advertisement
Australia markets closed
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • AUD/USD

    0.6522
    -0.0014 (-0.21%)
     
  • OIL

    82.51
    +1.16 (+1.43%)
     
  • GOLD

    2,234.90
    +22.20 (+1.00%)
     
  • Bitcoin AUD

    109,296.31
    +3,344.02 (+3.16%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • AUD/EUR

    0.6036
    +0.0005 (+0.09%)
     
  • AUD/NZD

    1.0899
    +0.0020 (+0.18%)
     
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NASDAQ

    18,277.00
    -3.84 (-0.02%)
     
  • FTSE

    7,972.43
    +40.45 (+0.51%)
     
  • Dow Jones

    39,759.76
    -0.32 (-0.00%)
     
  • DAX

    18,507.49
    +30.40 (+0.16%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     

Inspire Medical Systems, Inc. to Present at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Inspire Medical Systems
Inspire Medical Systems

MINNEAPOLIS, March 07, 2023 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the virtual KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023.

Inspire is scheduled to present at 9:00 a.m. Eastern Time. The presentation will be accessible via a live webcast here.

A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire’s Investor website at https://investors.inspiresleep.com.

ADVERTISEMENT

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Investor and Media Contact
Ezgi Yagci
Vice President, Investor Relations
ezgiyagci@inspiresleep.com
617-549-2443